NSRX Nasus Pharma Ltd.
Company Analysis
Latest News
🔴 Nasus Pharma is trading 6.1% down today extending recent volatility
Nasus Pharma is trading 6.1% down at $2.75 in pre-market, extending last week’s volatility after speculative gains and a subsequent pullback. • The move...
🟢 Nasus Pharma is trading 11% up today on speculative interest amid light news flow
Nasus Pharma is trading 11% higher at $3.34 on speculative interest and technical buying, despite a lack of fresh filings or press releases as of July 10,...
🟢 NSRX is trading 6.3% up today on a continued technical rebound
NSRX is trading at $3.27 (+6.3%) in after-hours, extending a rebound that followed its sharp 11.21% drop to $3.05 on July 7. * The move appears driven by a...
🟢 NSRX is trading 9.8% up today on a technical rebound after the July 7 selloff
NSRX is trading 9.8% up at $3.35 as the stock stages a technical recovery following a sharp decline in the previous session. • The move follows an 11.21% drop...
🟢 NSRX is trading 8% up today with no clear catalyst identified
NSRX is trading 8% up at $3.29 in pre-market, suggesting a technical rebound after recent weakness as no company-specific catalysts were identified. • The...
🔴 NSRX is trading 7.7% down today, extending recent losses with no clear catalyst
NSRX is trading 7.7% down at $3.17 in mid-session trading, extending modest losses from recent days with no clear company-specific catalyst identified. • No...
🟢 NSRX is trading 5.4% up today, extending a multi-day rebound amid a broader market rally
NSRX is trading 5.4% up today at $3.50, extending a multi-day rebound from the low-$3 range amid a broader risk-on mood in U.S. equities. • The move appears...
🔴 NSRX is trading 6% down today as it gives back recent gains ahead of investor events
NSRX is trading at approximately $3.11 (6% down), pulling back as it gives back a portion of its recent rally leading into upcoming investor presentations. •...
Nasus Pharma Ltd. Q1 2026 Earnings Preview: What Analysts Expect on June 24, 2026
Consensus revenue is projected at $0.00 million as the company remains in its pre-commercial development phase, with EPS expected at -$0.27 against a current...